Recently, the global gene sequencing market has seen the release of multiple high-throughput sequencing products and updates to technical roadmaps.01GeneMind:Launch of the Global Unbiased Q50 Innovative Sequencing Chemistry CMS Technology and CMS Kit ProductsCMS (Cross Mountains and Seas) is an innovative sequencing chemistry technology launched by GeneMind. This technology relies onInnovative technologies such as novel polymerase mutationsSignificantly enhance sequencing capabilities in challenging genomic regions, optimize whole-genome sequencing coverage uniformity, and achieve unbiased Q50-level (99.999%) accuracy data output across the entire genome. SURFSeq 5000 CMS Sequencing Kit V1.0 series products integrate CMS and Lightning Chemistry Plus technologies to achieve ultimate coverage: breaking through the "difficult-to-sequence regions" bottleneck with uniform global coverage; ultimate accuracy: Q40>95%, Q50>70%; ultimate efficiency: 1500Gb+ daily output, PE150 fastest <16hrs.CMS technology excels in ultra-low frequency mutation detection, fragment abundance quantification, and coverage of challenging genomic regions, empowering key applications in early cancer screening and diagnosis, recurrence monitoring, post-transplant rejection monitoring, rare disease diagnosis, and immune repertoire research within clinical and scientific fields.
Illumina:Released the 18-month technology roadmap for the NovaSeq X system
The core improvements of the NovaSeq X system include:In H1 2026, a brand-new 5 billion (5B) Reads flow cell will be launched, along with support1.5 Billion (1.5B) Reads 600-Cycle Kit with Longer Read Length;2027H1, Simplex Sequencing Q50, Duplex Sequencing Q70; Flow cell output will increase by up to 40%, with runtime reduced by approximately 30%. The standard 10B flow cell output will increase to 14 billion reads, with a turnaround time of less than 20 hours. The maximum specification flow cell output will increase to 35 billion reads.
03Element Biosciences：Launches First High-Throughput Desktop Sequencing System VITARI
Adopts a dual flow-cell design; in PE150 sequencing mode, a single chip produces 1.5TB of data, with a total output of 3TB for a single run (dual chips); running time is approximately 36 hours; sequencing quality Q30 exceeds 90%; enables $100 human whole genome sequencing.Expected to begin shipping in the second half of 2026, with a price of $689,000.
04Ultima Genomics：Launch of the UG200 Ultra-High-Throughput Gene Sequencer Series
Including two configurations: UG200 (single wafer) and UG200 Ultra (dual wafer).This series adopts the Solaris 2.0 solution, eliminating the emulsion PCR (ePCR) step. Core capabilities include: doubling single-wafer output to 20 billion reads (20B), with the UG200 Ultra capable of sequencing over 60,000 human whole genomes annually, achieving SNV Q60 sequencing accuracy.The starting price of UG200 is $850,000, and users can convert the UG200 to the double-flux UG200 Ultra through on-site upgrades in the future.
05
Swiss Rockets：Plan to Launch CoolMPS 600 Gene Sequencer
- Throughput and Run Time: Includes two independent flow cells, producing up to 2.4 Tb of data within two days in a single run under SE600 bp mode. This is equivalent to 24 human genomes (30X coverage).
- Read Length and Sequencing Cost: At launch, SE600 bp and PE150 bp sequencing will be supported. When the system is fully operational, the cost to sequence a single human genome with 30X coverage will be less than $100.
Expected to be launched in Q2 2026.
The above information is summarized as follows:
01 MGI Sells Subsidiary Complete Genomics (CGI)MGI Tech Recently Announced a Major Strategic Adjustment, Transferring Ownership of Its U.S. Subsidiary CGI to a Swiss Entity.1.Transaction Details: MGI R&D HK, a wholly-owned subsidiary of MGI, signed an agreement with Swiss Rockets AG,Proposes to Sell 100% Equity Interest in CGI for Approximately US$50 Million After Asset StrippingUpon completion of the transaction, CGI will become a wholly-owned subsidiary of Swiss Rockets and operate independently.2. Technical Licensing Adjustment: Swiss Rockets has obtained the exclusive license for the CoolMPS sequencing technology outside the Asia-Pacific and Greater China regions, and additionally secured the exclusive license for Standard MPS technology in the United States and Canada. MGI Tech is expected to receive no less than 120 million U.S. dollars in licensing fees during the licensing period.3. Strategic Significance: MGI Tech stated that this move aims to proactively address geopolitical risks and regulatory uncertainties in overseas markets (especially the North American market, such as the NDAA bill), optimize asset structure, and divest loss-making units. Through a "reverse licensing" arrangement, MGI Tech retains permanent, royalty-free usage rights to 205 patents held by CGI, ensuring continuity of its technological system.
02 Grail Announces Progress in Multi-Cancer Early Detection (MCED)Grail recently announced the preliminary results of the highly anticipated UK NHS-Galleri trial, causing a strong market reaction.Test results: This large trial involving 142,000 people did not meet its primary endpoint, namelyFailed to significantly reduce the incidence of stage III and IV cancers statisticallyHowever, Grail emphasized a favorable trend of reduced Stage IV diagnoses observed across 12 lethal cancer types (with a reduction of over 20% in the second and third rounds of screening), and the overall cancer detection rate improved fourfold compared to standard care.Commentary: Experts hold divergent views on this matter. Some experts consider the trial results to be "negative" and warn against overinterpreting favorable trends. However, some biostatisticians have pointed out that cancer screening is extremely complex, and the trial period may be too short to simply label it as a failure.Market and Business Impact: Affected by this news, Grail's stock price once plummeted by 46%. Nevertheless,Grail States Trial Results Will Not Impact Its PMA Submission to the U.S. FDA, and plans to expand the size of its U.S. sales and medical teams by 30% to meet market demand. In terms of finance, Grail’s testing revenue for the Galleri product in 2025 achieved a year-over-year growth of 28%-31%.
*Note: This article is intended for industry learning and exchange and does not constitute any investment advice. Media friends, please wait 24 hours after the article is published before reprinting, and it is limited to the WeChat Official Account platform. Please do not reprint it on other online platforms such as Xueqiu, Jianshu, Zhihu, self-built websites, or self-built apps without permission. Your understanding and cooperation are appreciated. If necessary, please apply for reprint authorization in the backstage.
| 
